You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD19,CD20,BCMA

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non-Hodgkin's Lymphoma (Disorder), Acute Lymphoid Leukemia, Disease (Disorder) Trial in Louisville, Houston (1A46 Injection)

Recruiting
  • Non-Hodgkin's Lymphoma (Disorder)
  • Acute Lymphoid Leukemia, Disease (Disorder)
  • 1A46 Injection
  • Louisville, Kentucky
  • +1 more
Aug 1, 2022

B-cell NHL, CLL Trial (CARCIK-CD19)

Not yet recruiting
  • B-cell NHL
  • CLL
  • CARCIK-CD19
  • (no location specified)
May 19, 2023

B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory Trial in Beijing, Tianjin (LCAR-AIO cells product)

Recruiting
  • B-cell Lymphoma Recurrent
  • B-cell Lymphoma Refractory
  • LCAR-AIO cells product
  • Beijing, Beijing, China
  • +1 more
Apr 1, 2022

Relapase and Refractory B-cell Non-Hodgkin's Lymphoma, Decitabine-primed Tandem CD19/CD20 CAR T Cells Trial in Beijing

Recruiting
  • Relapase and Refractory B-cell Non-Hodgkin's Lymphoma
  • Decitabine-primed Tandem CD19/CD20 CAR T Cells
  • Decitabine-primed Tandem CAR19/20 engineered T cells
  • Beijing, Beijing, China
    Biotherapeutic Department of Chinese PLA General Hospital
Mar 24, 2022

Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto

Not yet recruiting
  • Multiple Sclerosis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Palo Alto, California
    Stanford Multiple Sclerosis Center
Nov 13, 2023

Follicular Lymphoma, Mantle Cell Lymphoma Trial in Rouen (Determination of COVID-19 vacciantion efficacy)

Completed
  • Follicular Lymphoma
  • Mantle Cell Lymphoma
  • Determination of COVID-19 vacciantion efficacy
  • Rouen, France
    Centre Henri Becquerel
Dec 22, 2022

Solid Tumor, Adult Trial (CF33-CD19 IT, CF33-CD19 IV, Blinatumomab)

Not yet recruiting
  • Solid Tumor, Adult
  • CF33-CD19 IT
  • +2 more
  • (no location specified)
Sep 26, 2023

WOE of Anti-CD20 Therapies

Not yet recruiting
  • Multiple Sclerosis
  • (no location specified)
Oct 31, 2023

Systemic Lupus Erythematosus Trial (CD19 CAR-T cell infusion)

Not yet recruiting
  • Systemic Lupus Erythematosus
  • CD19 CAR-T cell infusion
  • (no location specified)
Oct 24, 2023

Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV Trial in Denver,

Recruiting
  • Lupus Nephritis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Denver, Colorado
  • +1 more
Jul 7, 2023

Systemic Lupus Erythematosus, Autoimmune Diseases Trial in Hangzhou (Assigned Interventions CD19/BCMA CAR T-cells)

Recruiting
  • Systemic Lupus Erythematosus
  • Autoimmune Diseases
  • Assigned Interventions CD19/BCMA CAR T-cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital,College of Medicine, Zhejiang Univ
Aug 31, 2021

Systemic Lupus Erythematosus Trial (CD19 Universal CAR-?d T Cells)

Not yet recruiting
  • Systemic Lupus Erythematosus
  • CD19 Universal CAR-γδ T Cells
  • (no location specified)
Oct 24, 2023

Multiple Myeloma Trial in Shanghai (GC012F injection)

Unknown status
  • Multiple Myeloma
  • GC012F injection
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
Sep 21, 2021

Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma Trial in United States (P-CD19CD20-ALLO1, Rimiducid)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • +5 more
  • La Jolla, California
  • +7 more
Aug 25, 2023

Diffuse Large B-cell Lymphoma Trial in Hangzhou (Metabolically Armed CD19 CAR-T cells)

Recruiting
  • Diffuse Large B-cell Lymphoma
  • Metabolically Armed CD19 CAR-T cells
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Nov 1, 2023

B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Charleston (Cyclophosphamide injection, Fludarabine

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia
  • Cyclophosphamide injection
  • +2 more
  • Charleston, South Carolina
    Hollings Cancer Center at Medical University of South Carolina
Jan 18, 2023

Lymphoma Trial in Houston (PCV20)

Not yet recruiting
  • Lymphoma
  • PCV20
  • Houston, Texas
    M D Anderson Cancer Center
Sep 20, 2023

Lymphoma, B-Cell, Lymphoma, Non-hodgkins, Chronic Lymphocytic Leukemia Trial run by the NCI (Anti-cluster of differentiation 19

Terminated
Has Results
  • Lymphoma, B-Cell
  • +3 more
  • Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptors (CAR) and Anti-cluster of differentiation 20 (CD20)-CAR T cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 26, 2022

Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Spain (ARI0003)

Not yet recruiting
  • Refractory Non-Hodgkin Lymphoma
  • Relapsed Non-Hodgkin Lymphoma
  • ARI0003
  • Santiago De Compostela, A Coruña, Spain
  • +6 more
Oct 24, 2023

Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small

Recruiting
  • Relapsed or Refractory CD19+ B-cell Lymphoma
  • +2 more
  • TBI-2001
  • +2 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jul 26, 2023

POMES Syndrome, Relapsed and Refractory POMES Syndrome Trial in Shanghai (anti-CD19/BCMA CAR-T cells, Fludarabine,

Active, not recruiting
  • POMES Syndrome
  • Relapsed and Refractory POMES Syndrome
  • anti-CD19/BCMA CAR-T cells
  • +2 more
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
Aug 5, 2021

Non Hodgkin Lymphoma Trial (TMhuCART19-IL18)

Not yet recruiting
  • Non Hodgkin Lymphoma
  • TMhuCART19-IL18
  • (no location specified)
Aug 2, 2023

B-cell Acute Lymphoblastic Leukemia Trial (CD19-CAR_Lenti_ALLO)

Not yet recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • (no location specified)
Oct 10, 2023

B-cell Non Hodgkin Lymphoma Trial in Augsburg, Cologne, Hamburg (MB-CART2019.1 Dose level 1, MB-CART2019.1 Dose level 2)

Active, not recruiting
  • B-cell Non Hodgkin Lymphoma
  • MB-CART2019.1 Dose level 1
  • MB-CART2019.1 Dose level 2
  • Augsburg, Bavaria, Germany
  • +2 more
Jun 13, 2022

B-Cell Non Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia Trial in Hanoi (anti-CD19 CAR T-cells)

Recruiting
  • B-Cell Non Hodgkin Lymphoma
  • B-Cell Acute Lymphoblastic Leukemia
  • anti-CD19 CAR T-cells
  • Hanoi, Vietnam
    Vinmec Research Institute of Stem Cell and Gene Technology
Sep 5, 2023